Fig 1.
Overall trends in rate of women in receipt of any vitamin D per 1000 women for (i) GMS eligible national population and (ii) GMS breast cancer patients for years 2005–2011 with stratification by age group. Relative risks (RR) along with confidence intervals (CI) are also presented comparing 2011 to 2005 where the referent group for each RR is the group specific level in 2005.
Table 1.
NCRI-PCRS prescribing data: Number of female breast cancer patients with breakdown by vitamin D/tamoxifen/aromatase inhibitors (AI) users and the percentage of AI users who had a vitamin D claim.